| Abstract: | With better understanding of the role of type 2 inflammation in allergic asthma, there has been progress made in the development of new biologic therapies targeting these specific pathways. This review will consider diagnostic criteria for using biologic therapies for pediatric asthma with special emphasis on populations that are likely to benefit the most from particular therapies. With the exception of the anti‐immunoglobulin E, omalizumab, very few studies have been published on the efficacy and safety of biologic therapies in children, particularly anti‐interleukin‐5 (IL5) and anti‐IL4/IL13 therapies. The review will highlight the scarcity of published data in pediatric‐specific populations. In addition, we will consider the cost‐effectiveness as well as potential long‐term consequences of biologic therapies in pediatric asthma. |
